Vice President Jennifer Che gave a talk at the Swiss Patent Attorney Associations and the Swiss Professional Attorney Association of Industrial Patent Attorneys (VESPA/VIPS) annual autumn seminar about key upcoming changes in China’s new Patent Law as well as other related new measures that are particularly relevant to pharma/biotech companies, including patent term extension, patent linkage, post-filing data, litigation reform, and patent eligibility in the biotech/pharma area.

我們過去活動

Eagle IP is Coming Back to LSPN in Boston!

2025年4月24日

AIPLA Women in IP Global Networking Event in Hong Kong

2025年4月3日

Talk at Hong Kong Christian Service

2024年10月31日

Talk for HKUST Entrepreneurship 101 Training Program

2024年10月31日

IP Training Programme on patent commercialization and technology transfer

2024年10月8日

‘Unlocking Patent Law: Exploring IP Career Paths’

2024年7月20日

Recommended Insights

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

2025年2月4日
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
閱讀更多 >

New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference

2024年3月21日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]
閱讀更多 >

What is the difference between an Invention Patent and a Utility Model Patent?

2021年8月13日
There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]
閱讀更多 >

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

2018年11月23日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]
閱讀更多 >
Top crossarrow-right